2.1 Controlled Substances Act & DEA Scheduling

Why Scheduling Drives Everything on the PA MPJE

The classification of a medication as a controlled substance drives nearly every operational rule a Pennsylvania pharmacist applies: how the drug may be ordered, prescribed, dispensed, refilled, stored, inventoried, returned, and reported. The federal framework is the Controlled Substances Act (CSA) of 1970, codified in Title 21 United States Code (21 USC) §§ 801–971 and implemented by the Drug Enforcement Administration (DEA) under 21 CFR Parts 1300–1321. Pennsylvania's parallel statute is The Controlled Substance, Drug, Device and Cosmetic Act, 35 P.S. §§ 780-101 et seq. (Act 64 of 1972), administered through the Department of Health and the State Board of Pharmacy. The PA MPJE does not separate federal from state questions; the candidate must apply the law that produces the stricter result. When PA is stricter (e.g., e-prescribing mandated for CII–CV since October 24, 2019; PDMP query required for opioids and benzodiazepines), PA controls. When federal is stricter, federal controls.

The Three Scheduling Criteria

The CSA assigns a substance to one of five schedules based on three statutory findings:

1. Abuse potential — actual or relative potential for abuse.
2. Accepted medical use — whether the substance has a currently accepted medical use in treatment in the United States.
3. Dependence liability — the degree of psychological or physiological dependence the substance may create.

The U.S. Attorney General (acting through the DEA Administrator) holds federal scheduling authority and must obtain a scientific and medical evaluation from the Secretary of Health and Human Services (HHS), conducted by the FDA; the HHS scientific and medical findings are binding on the Attorney General. In Pennsylvania, 35 P.S. § 780-104 authorizes the Secretary of Health (coordinating with the Department of Drug and Alcohol Programs) to add, delete, or reschedule substances to keep Pennsylvania aligned with federal scheduling.

The Five Schedules: Criteria and Examples

Key Per-Schedule Dispensing Rules

• Schedule I — No prescriptions permitted. CI substances have no accepted medical use and may only be handled under a DEA Schedule I researcher registration. They cannot be dispensed to a patient under any circumstance, even with a prescriber order.
• CII — Dispensable by prescription, no refills (21 CFR 1306.12). Two federal partial-fill carve-outs apply: (1) a pharmacist may partially fill a CII prescription if the patient cannot tolerate the full quantity or the pharmacy lacks sufficient stock, by noting the reason on the reverse of the prescription (or documenting electronically in an EPCS record), with the remainder fillable within 72 hours; and (2) a prescription for a compounded CII for direct administration to a long-term care (LTC) or terminally ill patient may be partially filled, with the remainder fillable within 72 hours. PA follows these federal partial-fill rules.
• CIII–CV — Refills up to 5 times within 6 months of the date of issue (21 CFR 1306.22). After 5 refills or 6 months, whichever comes first, the prescription is void and a new prescription is required.
• E-prescribing of controlled substances (EPCS) — Authorized under 21 CFR Part 1311; PA has mandated e-prescribing of all CII–CV controlled substances since October 24, 2019, with limited statutory exceptions (e.g., temporary technological failure, hospice, veterinary).

Pennsylvania's Parallel Statute and How PA Aligns

35 P.S. § 780-104 adopts the federal schedules by reference and empowers the Secretary of Health to add, reschedule, or delete substances to keep PA aligned with federal changes. When the DEA reschedules a substance (e.g., hydrocodone combination products from CIII to CII in October 2014; tramadol placed in CIV in 2014; gabapentin remained non-controlled federally), PA's schedule moves in lockstep through state regulatory action. PA also layers state-specific monitoring on top of federal scheduling:

• Gabapentin — Not federally scheduled and not in PA Schedules I–V. Pennsylvania does not require gabapentin dispensing to be reported to ABC-MAP (reporting is limited to Schedules II–V controlled substances). Some other states schedule gabapentin or mandate PDMP reporting — that is not PA law.
• Ephedrine and pseudoephedrine — Tracked under federal Combat Methamphetamine Epidemic Act (CMEA) limits and PA precursor chemical rules; PA enforces daily and 30-day purchase limits and tracks sales.
• Naloxone — Non-controlled; PA's Act 139 of 2014 (David's Law) authorizes dispensing under a standing order issued by the PA Secretary of Health / Physician General, without an individual prescription.

Common MPJE Scheduling Traps

1. The "Schedule I prescription" question — Any answer suggesting a CI may be dispensed on a prescription is wrong. CI = no accepted medical use, no prescribing.
2. The gabapentin trap — Federally non-controlled and not Schedule V in PA, and not ABC-MAP-reportable. A question asking about gabapentin should not apply Schedule V handling or PDMP reporting rules; contrast with states that do schedule or monitor gabapentin.
3. CII refills — A CII prescription cannot be refilled under ordinary circumstances; the only federal carve-out is the LTC/terminally-ill compound-for-direct-administration partial fill.
4. Hydrocodone combination products (HCPs) — Schedule II federally and in PA since October 6, 2014. Any answer describing HCPs as Schedule III reflects a pre-2014 rule and is wrong on the 2026 exam.
5. Fentanyl — Schedule II; despite its high potency, it has accepted medical use, distinguishing it from Schedule I.
6. Dronabinol (synthetic THC, Marinol) — Schedule III federally and in PA, while marijuana remains Schedule I federally. Do not confuse the two.